untreated and sCD40L-activated EC involved interactions between the 43bp DNA and MeCP2.
In addition, we found that other CpG binding proteins may also interact with this region of the promoter. Taken together, this is the first demonstration that CpG binding transcriptional repressor proteins including MeCP2 may be of importance in VEGF biology.
INTRODUCTION
Vascular endothelial growth factor (VEGF), a major angiogenesis factor, is also a multifunctional cytokine that has been shown to be of importance in several developmental, physiological and inflammatory processes in the kidney (8, 18, 30, 39, 51, 58) . It is expressed in human cells as a polypeptide of either 206, 189, 165, 145, and 121 amino acids (aa), arising from the alternative splicing of a single gene (8, 18, 35, 63) . All the activities of VEGF are thought to be mediated mainly through three high affinity receptor tyrosine kinases, KDR/Flk-1, Flt-1 and neuropilin that are expressed by the vascular endothelium as well as other cell types including renal epithelial cells (14, 21, 31, 55, 58, 69) .
In the normal human kidney, VEGF is expressed mainly by podocytes, tubular epithelial cells and endothelial cells (EC) (7, 17, 21, 59) . Increases in VEGF expression are well established to be functional for renal vasculogenesis and normal renal development in the embryo (30, 39, 64) . However, recent data also suggest that VEGF has a major role in glomerular diseases (25, 46, 61) . In an experimental model of nephritis, blockade of VEGF in vivo was found to increase intrarenal apoptosis, impair glomerular capillary repair and result in proteinuria (48) . In humans, blockade of VEGF with anti-VEGF for the treatment of metastatic renal cancer was found to result in proteinuria (67) ; and it has been proposed that the use of high concentrations of anti-VEGF may be limited by this "renal" side effect.
Additional studies have further confirmed that glomerular capillary function is under strict control by VEGF within the glomerulus (17, 38) . When intraglomerular VEGF levels decrease in a transgenic mouse, capillary EC were found to swell, capillary loops collapsed and proteinuria developed (60) . Also, consistent with this observation conditional VEGF isoform knockout mice are reported to have impaired glomerular filtration (39) . Furthermore, in humans with preeclampsia it was found that circulating levels of a VEGF antagonist rise (36, 40) . This molecule which was identified as the VEGF receptor Flt-1 binds to circulating VEGF and results in a decrease in local concentrations of VEGF in the kidney (40) . Decreasing local intrarenal concentrations of VEGF was demonstrated to be associated with glomerular capillary leak and proteinuria, a characteristic finding in preeclampsia (40) . Nevertheless, it is also notable that overexpression of intrarenal expression of VEGF can also be associated with proteinuric diseases including HIV nephropathy as well as allograft rejection (2, 26, 34, 51, 57) . Thus, it is likely that the maintainence of normal glomerular capillary function is dependent on some threshold level(s) of intrarenal expression of VEGF.
Recently, we reported that the interaction between CD40 ligand (CD40L) and CD40 induces the expression of VEGF by EC (41, 53). CD40, a type I transmembrane-glycoprotein member of the tumor necrosis factor receptor (TNF-R) gene family is expressed by many cell types, including renal epithelial cells and EC (1, 24, 37, 65, 66, 68) . CD40L is expressed as a cell surface molecule by activated CD4 + T cells and platelets (23, 47) and also exists in plasma in a soluble circulating form of unknown function. Thus, it is possible that ongoing interactions between CD40L and CD40 may play a role in the maintenance of normal EC VEGF expression. Moreover, it is also possible that CD40L-CD40 interactions are functional for the increased levels of VEGF that occur in inflammation (13, 51, 53).
In the present study, we have identified the CD40 responsive region of the VEGF promoter and we show that this region contains a CpG island overlying the major transcription start site. Recent evidence suggests that CpG dinucleotides within a promoter plays a significant role in gene silencing via an ability to bind transcriptional repressor proteins (3, 29) . We demonstrate that the CpG island within the CD40-responsive region of the VEGF promoter binds the transcriptional repressor protein Methyl CpG Binding Protein-2 (MeCP2), and perhaps other CpG binding proteins; and we show that MeCP2 is removed following CD40-dependent activation of EC. We suggest that these observations for the first time define an important role for CpG islands and transcriptional repressors in the regulation of VEGF in EC. Western Blot Analysis. Protein samples were mixed with 2X sample buffer (125 mM Tris-HCl, pH 6.8, 20% glycerol, 10% b-mercaptohanol, 4% sodium dodecyl sulfate SDS), and 0.0025% bromophenol blue), boiled, and run on 7.5% polyacrylamide gel with Tris-glycin-SDS running buffer (Bio-Rad) as described (49) . Size-separated proteins were transferred to a PVDF membrane (NEN Life Science Product, Boston, MA) . For immunodetection, the membranes were blocked with 5% milk in PBS-Tween 20 and then coated with primary antibody. After washings, the membranes were incubated with peroxidase-linked secondary antibody and the reactive bands were detected by chemoluminescent substrate (49) .
EXPERIMENTAL PROCEDURES

Reagents
Nuclear extract preparation, and electrophoretic mobility shift assays (EMSAs). HUVEC grown
to confluence were incubated in the presence of EBM ® basal medium (Clonetics) containing 0.5% FBS, but no other supplements for 24h. Subsequently the cells were cultured for 30 to 180 min in the absence or presence of sCD40L at 37ºC in 5-10% CO 2 . Crude nuclear extracts were prepared and EMSAs were performed as described (42, 50) . Briefly, the following components were mixed and preincubated at room temperature for 20 min: 1-2 µg nuclear extract protein was incubated with 1 µg of poly(dA-dT) in a buffer containing 8 mM Tris (pH 7.5), 10 mM KCL, 1% glycerol, 1 mM EDTA, and 10 mM dithiothreitol (DTT) (Sigma Chemical Co., St Louis, MO).
Antibodies for supershift studies (1 or 2 µg) were added at this time. In some experiments, recombinant human MeCP2 protein (a gift Alan Wollfe, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland) was added in place of the nuclear extracts.
After 20 min at room temperature, the labeled probe (~0.1 ng) was added, and incubation was continued for 20 min at room temperature. The samples were resolved by electrophoresis on a 7% polyacrylamide gel, and expression was quantified by densitometry using an Alpha Imager 2000 system (Alpha Innotech, San Leandro, CA). For quantification by densitometry, signals were standardized to the intensity of the free probe.
The radiolabeled oligonucleotide used in EMSAs was the PCR-generated fragment (bp -25 to +18, relative to the transcription start site) of the VEGF promoter. Methylation was performed in vitro with Sss I (New England Biolabs, Inc., Beverly, MA) in the presence or absence of the methyldonor S-adenosylmethionine, according to the manufacturer's instructions and as described (10) . Methylated oligos were labeled by employing a Klenow fill-in reaction and purified for EMSA.
RESULTS
Ligation of CD40 with sCD40L induces VEGF promoter activity. In order to confirm that CD40
signals induce VEGF transcription, we initially transiently transfected HUVEC with a full-length (2.6 kb) VEGF promoter-reporter construct (bp -2361 to +298, relative to the transcription start site) using a standard lipofection procedure. Following 24 hr incubation in the presence or absence of human sCD40L, luciferase activity was assessed in lysates of transfected cells, using equal amounts of total cellular proteins for each sample. We found a 4-to 6-fold induction in the luciferase activity following treatment with sCD40L, as compared to untreated cells or mock controls ( Figure 1A) . In contrast, activation of HUVEC with the cytokines IFN-g, IL-1, IL-4, and TNF-a did not mediate any VEGF transcriptional activation in concentrations that markedly induced the expression of E-selectin, ICAM-1 and VCAM-1 (data not shown).
CD40 signals are reported to regulate the transcription of many genes, predominantly via NF-kB or AP-1-dependent mechanisms. Analysis of the VEGF promoter sequence revealed a single major transcription start site, containing several binding sites for HIF-1, Sp-1, AP-1 and AP-2, but no putative NF-kB binding sites as previously described (42, 63) . To define the region of the VEGF promoter responsive to CD40-signaling, we next transfected HUVEC with deletion constructs developed by sequential 5' deletions of the 2.6 kb promoter to exclude potential CD40 regulatory sites. We generated a 0.35kb construct which contains four Sp-1 binding sites but no AP-1 binding site and a 0.2kb construct that does not contain any putative NF-kB, AP-1 or Sp-1 binding sites (42) . As shown in Figure 1B , like the 2.6 kb VEGF promoter, there was strong induction of transcriptional activity of both 0.35-and 0.2-kb VEGF promoter-reporter constructs in response to sCD40L treatment of EC.
The CD40 regulatory element(s) resides in a 68 bp sequence of the human VEGF promoter.
We next addressed the specificity of CD40 ligation in the process of VEGF transcriptional activation, using Jurkat T cells that produce VEGF and either express cell surface CD40 
MeCP2 associates with a CpG island within the CD40-regulated region of the VEGF promoter.
Through a computerized search of genomic DNA libraries (Blast), and by using MatInspector V2.2 (Genomatrix), (52) Figure 3) . It has been previously demonstrated that this particular CpG island, if methylated, is a binding site for the abundant chromosomal protein MeCP2 which has been described as a potent transcriptional repressor (11, 15).
We performed EMSA using the 43 bp sequence as a probe and found that the While it is possible that several methyl CpG binding proteins interact with the methylated 43bp region of the VEGF promoter, we found that this CpG island has the capacity to interact with MeCP2 (discussed above). To determine if the nuclear protein-DNA complex(es) involves MeCP2-CpG interactions, we first performed supershift analysis using a polyclonal anti-MeCP2 antibody in EMSA. Extracts from EC again formed complexes with the methylated 43bp probe;
and there was a major supershift of one of the three bands with the anti-MeCP2 antibody ( Figure   5A ). The other two bands were also supershifted but to a lesser extent. In contrast, there was no supershift of the complexes using a control Ig antibody. We also treated EC with sCD40L and again evaluated the binding and supershift of nuclear extracts using the anti-MeCP2 antibody. As illustrated in Figure 5B , treatment with sCD40L resulted in a reduction in the intensity of at least one band (versus untreated EC, Figure 5A ); and anti-MeCP2 resulted in a partial supershift of the other remaining bands. We interpret this finding to indicate that MeCP2 in sCD40L-treated cells may still interact with the VEGF promoter as a part of a complex with other methyl CpG binding
proteins. In addition, there is a weak band that is perhaps not supershifted by anti-MeCP2
( Figure 5B ), indicating that not all the complex(es) in sCD40L-treated cells that bind the VEGF promoter construct interact with MeCP2. By Western blot analysis, we confirmed that MeCP2 is an abundant nuclear protein in extracts from both untreated and sCD40L-treated EC ( Figure 5C ).
Furthermore, we found that purified recombinant human MeCP2 protein formed a single complex with the methylated (but not the unmethylated) 43bp DNA probe in EMSA ( Figure   5D ). This 43bp-MeCP2 protein-DNA complex, was supershifted following incubation with the polyclonal anti-MeCP2 antibody ( Figure 5D ). Thus, MeCP2 is an abundant nuclear protein in untreated and sCD40L-treated EC; and has the capacity to bind to the methylated 43bp VEGF promoter sequence alone or as a complex with other nuclear proteins.
Taken together these data suggest that methylated CpG dinucleotides within a 43bp region of the VEGF promoter bind MeCP2 and perhaps other nuclear CpG binding proteins.
Moreover, ligation of CD40 may result in the release of CpG binding proteins from the methylated CpG dinucleotides and thus may regulate VEGF transcriptional activation. Since this region of the VEGF promoter overlies the major transcription start site, these findings suggest that transcriptional repressors or/and the methylation status of CpG dinucleotides within the promoter are likely to be of importance in VEGF biology
DISCUSSION
The expression of CD40 is prominent on many cell types in pathologic processes known to be associated with high levels of VEGF, including renal EC and tubular epithelial cells at sites of inflammation (16, 37, 51, 54, 66) . CD40L-CD40 interactions result in several intracellular signals in EC that promote activation responses including the expression of the angiogenesis factor VEGF (12, 41, 53, 62) . In this study, we have identified a CD40-responsive element for VEGF expression in EC and we show that it resides within a 68bp region of the VEGF promoter. Figure 6 ). MeCP2, which is an abundant nuclear protein, has the ability to bind to the CpG island within the identified critical region of the VEGF promoter. Ligation of CD40 is well established to activate NF-kB and NFkB-like transcription factors, including the NF-kB family members p50, relA, and c-Rel (19, 56) .
In addition, CD40 ligation results in the activation of the inducible trancription factor complex, AP-1, typically consisting of heterodimers between Jun and Fos proteins (19, 27) . Thus, any one of several CD40-regulated transactivators may interact with MeCP2 resulting in its removal from the VEGF promoter. Indeed, the identified 68bp CD40-responsive region of the VEGF promoter 
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